Comparing PRUNE2 and PCA3 expression in prostatic adenocarcinoma with expression in normal prostate (all relative to endogenous housekeeping controls), we found consistent trends for both genes in multiple assays, with lower expression of PRUNE2 in tumor as compared with normal prostate and higher expression of PCA3 in tumor as compared with normal prostate (Figure 1—source data 1). The gene discussed is PRUNE2; the disease is prostate adenocarcinoma.